 |
IRVINE, Calif.--(BUSINESS WIRE)--Cortex Pharmaceuticals, Inc. (AMEX:COR) received the formal letter from the U.S. Food and Drug Administration on Monday, October 23, 2006 regarding the lifting of the clinical hold on Cortex’s lead product candidate, AMPAKINE® CX717. The Company will host a conference call at 4:00 p.m. ET (1:00 p.m. PT) on Thursday, October 26th to review the steps it is taking to advance the development of CX717.
Those who wish to participate may do so by dialing 1-877-407-0782 in the United States and 201-689-8567 for international participants. A replay will be available for 45 days after the call and can be accessed by dialing 1-877-660-6853 for participants in the United States and 1-201-612-7415 for international participants and entering account number 286 and conference ID 218465 when prompted.
About Cortex Pharmaceuticals
Cortex, located in Irvine, California, is a neuroscience company focused on novel drug therapies for neurological and psychiatric disorders. The Company is pioneering a class of proprietary pharmaceuticals called AMPAKINE compounds, which act to increase the strength of signals at connections between brain cells. The loss of these connections is thought to be responsible for memory and behavior problems in Alzheimer’s disease. Many psychiatric diseases, including schizophrenia, occur as a result of imbalances in the brain’s neurotransmitter system. These imbalances may be improved by using the AMPAKINE technology. Cortex has alliances with N.V. Organon for the treatment of schizophrenia and depression and with Les Laboratoires Servier for the development of AMPAKINE compounds to treat the neurodegenerative effects associated with aging and disease, including Mild Cognitive Impairment, Alzheimer’s disease and anxiety disorders. (http://www.cortexpharm.com/)
Forward-Looking Statement
Note – This press release contains forward-looking statements concerning the Company’s research and development activities. The success of such activities depends on a number of factors, including the risks that CX717, or the Company’s other proposed compounds may at any time be found to be unsafe or ineffective for the indications under clinical testing and that clinical studies may at any point be suspended or take substantially longer than anticipated to complete. As discussed in the Company’s Securities and Exchange Commission filings, the Company’s proposed products will require additional research, lengthy and costly clinical testing and regulatory approval. AMPAKINE compounds are investigational drugs and have not been approved for the treatment of any disease.
Contacts
Cortex Pharmaceuticals, Inc.
Roger G. Stoll, Ph.D.
Chairman, President and CEO
949-727-3157
or
The Investor Relations Group
Damian R. McIntosh/Dian Griesel, Ph.D.
Media: Lynn Granito
212-825-3210
|
